AR004221A1 - Pirimidinas y triazinas amino sustituidas, procedimiento para su preparacion, composicion farmaceutica, proceso para preparar dicha composiciony uso de dichos compuestos para preparar un medicamento. - Google Patents
Pirimidinas y triazinas amino sustituidas, procedimiento para su preparacion, composicion farmaceutica, proceso para preparar dicha composiciony uso de dichos compuestos para preparar un medicamento.Info
- Publication number
- AR004221A1 AR004221A1 ARP960104776A ARP960104776A AR004221A1 AR 004221 A1 AR004221 A1 AR 004221A1 AR P960104776 A ARP960104776 A AR P960104776A AR P960104776 A ARP960104776 A AR P960104776A AR 004221 A1 AR004221 A1 AR 004221A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- prepare
- compounds
- preparation
- hydrogen
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- -1 AMINO Chemical group 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003918 triazines Chemical class 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Abstract
Las pirimidinas y triazinas amino sustituidas de la fórmula (I), donde R es un alquilo C1-6, amino, mono- o dialquilamino C1-6; R1 es hidrógeno,alquilo C1-6, alquenilo C3-6, hidroxi alquilo C1-6 ó alquiloxi C1-6-alquilo C1-6, R2 es alquiloC1- 6 mono o di C3-6 cicloalquilmetil, fenilmetil,fenilmetil sustituido, alquiloxi C1-6-alquilo C1-6, hidroxi alquilo C1-6 alquiloxicarbonil C1-6-alquilo C1-6, alquenilo C3-6, ó R1 y R2 tomados juntocon el átomo de nitrógeno al que estánunidos pu eden formar un grupo pirrolidinil, morfolinil o piperidinil; X es N ó CR3; R3 es hidrógeno o alquiloC1-6; R4 es fenil ó fenil sustituido; A es C(=O)-,(II), donde R5 y R6 son independientemente hidrógeno o alquilo C1-4, R7es hidrógen o o OH; R8 eshidrógeno o alquilo C1-6, que tienen propiedades antagonistas del receptor FLC; procedimiento para su preparación, las composiciones farmacéuticas quecontienen estos compuestos como ingredientes activos y procedimiento parasu prepara ción; y uso de dichos compuestos para preparar un medicamento paratratar los desórdenes referidos a la hipersecreción de FLC como por ejemplo, la depresión, ansiedad, abuso de sustancias.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US568795P | 1995-10-17 | 1995-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR004221A1 true AR004221A1 (es) | 1998-11-04 |
Family
ID=21717189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960104776A AR004221A1 (es) | 1995-10-17 | 1996-10-16 | Pirimidinas y triazinas amino sustituidas, procedimiento para su preparacion, composicion farmaceutica, proceso para preparar dicha composiciony uso de dichos compuestos para preparar un medicamento. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6288060B1 (es) |
| EP (1) | EP0863882B1 (es) |
| JP (1) | JPH11513678A (es) |
| KR (1) | KR19990045744A (es) |
| AR (1) | AR004221A1 (es) |
| AT (1) | ATE212987T1 (es) |
| AU (1) | AU703096B2 (es) |
| CA (1) | CA2229710A1 (es) |
| DE (1) | DE69619125T2 (es) |
| DK (1) | DK0863882T3 (es) |
| ES (1) | ES2172681T3 (es) |
| MY (1) | MY113945A (es) |
| NO (1) | NO310771B1 (es) |
| NZ (1) | NZ320227A (es) |
| PT (1) | PT863882E (es) |
| TW (1) | TW378206B (es) |
| WO (1) | WO1997014684A1 (es) |
| ZA (1) | ZA968732B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094782B1 (en) | 1996-07-24 | 2006-08-22 | Bristol-Myers Squibb Company | Azolo triazines and pyrimidines |
| US6060478A (en) * | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| US6191131B1 (en) | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| US6124289A (en) * | 1996-07-24 | 2000-09-26 | Dupont Pharmaceuticals Co. | Azolo triazines and pyrimidines |
| US6313124B1 (en) | 1997-07-23 | 2001-11-06 | Dupont Pharmaceuticals Company | Tetrazine bicyclic compounds |
| DE19837387A1 (de) * | 1998-08-18 | 2000-02-24 | Aventis Res & Tech Gmbh & Co | 3'-Desoxypentopyranosyl-Nucleinsäure, ihre Herstellung und Verwendung |
| AU3357700A (en) * | 1999-02-16 | 2000-09-04 | E.I. Du Pont De Nemours And Company | Phenoxypyrimidine insecticides and acaricides |
| US6432989B1 (en) | 1999-08-27 | 2002-08-13 | Pfizer Inc | Use of CRF antagonists to treat circadian rhythm disorders |
| NZ517575A (en) | 1999-09-30 | 2004-04-30 | Neurogen Corp | Certain alkylene diamine-substituted heterocycles |
| US6525067B1 (en) * | 1999-11-23 | 2003-02-25 | Pfizer Inc | Substituted heterocyclic derivatives |
| WO2001062718A1 (en) * | 2000-02-25 | 2001-08-30 | Japan Tobacco, Inc. | Benzamide derivative and use thereof |
| AU2001280590A1 (en) | 2000-07-18 | 2002-01-30 | Neurogen Corporation | 5-substituted 2-aryl-4-pyrimidinones |
| AU8447301A (en) | 2000-09-19 | 2002-04-02 | Sumitomo Chemical Co | Pyrimidine compounds and their use |
| AU9625501A (en) | 2000-09-21 | 2002-04-02 | Bristol Myers Squibb Co | Substituted azole derivatives as inhibitors of corticotropin releasing factor |
| US20030055249A1 (en) * | 2001-07-17 | 2003-03-20 | Fick David B. | Synthesis and methods of use of pyrimidine analogues and derivatives |
| US6872827B2 (en) * | 2002-04-26 | 2005-03-29 | Chembridge Research Laboratories, Inc. | Somatostatin analogue compounds |
| TW200510394A (en) * | 2003-05-29 | 2005-03-16 | Synta Pharmaceuticals Corp | Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss |
| US20060024661A1 (en) * | 2003-07-30 | 2006-02-02 | The Regents Of The University Of California | Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2595697B1 (fr) * | 1986-03-13 | 1988-07-08 | Rousselot Cie | Derives de benzyl-pyrimidine, leur procede de preparation ainsi que les compositions en contenant |
| FR2692893B1 (fr) | 1992-06-24 | 1994-09-02 | Sanofi Elf | Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
| WO1995010506A1 (en) | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| TW574214B (en) | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
-
1996
- 1996-10-15 EP EP96934690A patent/EP0863882B1/en not_active Expired - Lifetime
- 1996-10-15 AU AU72929/96A patent/AU703096B2/en not_active Ceased
- 1996-10-15 AT AT96934690T patent/ATE212987T1/de not_active IP Right Cessation
- 1996-10-15 WO PCT/EP1996/004478 patent/WO1997014684A1/en not_active Ceased
- 1996-10-15 DE DE69619125T patent/DE69619125T2/de not_active Expired - Fee Related
- 1996-10-15 US US09/051,672 patent/US6288060B1/en not_active Expired - Fee Related
- 1996-10-15 JP JP9515515A patent/JPH11513678A/ja not_active Ceased
- 1996-10-15 PT PT96934690T patent/PT863882E/pt unknown
- 1996-10-15 ES ES96934690T patent/ES2172681T3/es not_active Expired - Lifetime
- 1996-10-15 KR KR1019980701986A patent/KR19990045744A/ko not_active Abandoned
- 1996-10-15 DK DK96934690T patent/DK0863882T3/da active
- 1996-10-15 CA CA002229710A patent/CA2229710A1/en not_active Abandoned
- 1996-10-15 NZ NZ320227A patent/NZ320227A/en unknown
- 1996-10-16 AR ARP960104776A patent/AR004221A1/es not_active Application Discontinuation
- 1996-10-16 TW TW085112616A patent/TW378206B/zh not_active IP Right Cessation
- 1996-10-16 MY MYPI96004287A patent/MY113945A/en unknown
- 1996-10-16 ZA ZA9608732A patent/ZA968732B/xx unknown
-
1998
- 1998-04-08 NO NO19981623A patent/NO310771B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2229710A1 (en) | 1997-04-24 |
| US6288060B1 (en) | 2001-09-11 |
| NO310771B1 (no) | 2001-08-27 |
| DE69619125T2 (de) | 2002-09-26 |
| DK0863882T3 (da) | 2002-05-06 |
| JPH11513678A (ja) | 1999-11-24 |
| WO1997014684A1 (en) | 1997-04-24 |
| EP0863882B1 (en) | 2002-02-06 |
| NO981623L (no) | 1998-06-09 |
| DE69619125D1 (de) | 2002-03-21 |
| EP0863882A1 (en) | 1998-09-16 |
| NO981623D0 (no) | 1998-04-08 |
| ES2172681T3 (es) | 2002-10-01 |
| ZA968732B (en) | 1998-04-16 |
| NZ320227A (en) | 1998-11-25 |
| AU703096B2 (en) | 1999-03-18 |
| AU7292996A (en) | 1997-05-07 |
| MY113945A (en) | 2005-12-14 |
| KR19990045744A (ko) | 1999-06-25 |
| ATE212987T1 (de) | 2002-02-15 |
| TW378206B (en) | 2000-01-01 |
| PT863882E (pt) | 2002-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR004221A1 (es) | Pirimidinas y triazinas amino sustituidas, procedimiento para su preparacion, composicion farmaceutica, proceso para preparar dicha composiciony uso de dichos compuestos para preparar un medicamento. | |
| AR005731A1 (es) | Tiofenopirimidinas, un procedimiento para su preparacion, el uso de las mismas como medicamento, una composicion que las contiene, un procedimientopara preparar dicha composicion, compuestos intermediarios para su exclusivo uso en dicho procedimiento y un procedimiento para su preparacion. | |
| AR008577A1 (es) | Pirazolopirimidinas, una composicion que las comprende, un procedimiento para preparar dicha composicion, un procedimiento para su preparacion,compuestos intermediarios de las mismas y un procedimiento para su preparacion | |
| ES2131106T3 (es) | Compuestos de benzotiazepina hipolipidemicos. | |
| CO5180642A1 (es) | Compuestos sustituidos de piperidina, procesos para su prepa racion, composiciones farmaceuticas que los contienen y su utilizacion | |
| AR008384A1 (es) | Composicion topica para el tratamiento de condiciones de la piel, uso del compuesto para la preparacion de un medicamento y metodo no-terapeuticos para el pulido de la piel y de suavizante capilar . | |
| AR029383A1 (es) | Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes | |
| ES2104708T3 (es) | Compuestos heterociclicos terapeuticos. | |
| ES2191048T3 (es) | Derivados de oxazolidinona y compuestos farmaceuticos que los contienen. | |
| BR9907270A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto | |
| BRPI0507644A (pt) | pirazolopirimidinas como inibidores de cinase dependente de ciclina | |
| IL108087A (en) | 2-substituted-3-azaindolyl- acrylonitrile and 3-(azaindolyl-methylene) oxindole derivatives, process for their preparation and pharmaceutical compositions containing them | |
| NO20050635L (no) | Nye tricykliske spiropiperidiner eller spiropyrrolidiner | |
| AR017182A1 (es) | Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen. | |
| MXPA05007494A (es) | Nuevos compuestos. | |
| BR9808017A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratar o câncer em um mamìfero e para a fabricação de um medicamento para o tratamento do câncer | |
| BR0109109A (pt) | Composto, uso do mesmo, processo para prepará-lo, composição farmacêutica, e, método de tratar um estado doentio mediado por ccr5 em mamìferos | |
| MX9300407A (es) | Derivados azabiciclicos usados en la fabricacion de medicamentos, composiciones que los contienen y procedimiento para su preparacion. | |
| UY27593A1 (es) | Nuevos compuestos | |
| BRPI0315958B8 (pt) | composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto | |
| GB0117396D0 (en) | Chemical compounds | |
| ATE340579T1 (de) | Methode zur behandlung oder prävention immunologischer erkrankungen und pharmazeutische zusammensetzung zur solchen anwendung | |
| AR002260A1 (es) | Compuestos derivados de acido [4-(indazol-3-il)-piperidin-1-il]-acetico, procedimiento para su preparacion, composicion farmacuetica que los contienen,el uso de los mismos en la preparacion de un agente terapeutico, metodo de tratamiento y compuestos intermediarios. | |
| BR0214649A (pt) | Derivados de aminotetralina como antagonistas do receptor muscarìnico | |
| AR029618A1 (es) | Compuestos de amida , procedimientos para prepararlos, las composiciones farmaceuticas que los contienen y el uso de dichos compuestos para la fabricacion de medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |